Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4155MR)

This product GTTS-WQ4155MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ4155MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15245MR IVTScrip™ mRNA-Anti-CD38, TAK-079(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA TAK-079
GTTS-WQ11226MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ5168MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ14678MR IVTScrip™ mRNA-Anti-MS4A1, SCT-400(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SCT-400
GTTS-WQ6837MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ15456MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ6699MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ1582MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-083
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW